Effect of high product ratio massive transfusion on mortality in blunt and penetrating trauma patients.

Published

Journal Article

BACKGROUND: Recent data suggest that massively transfused patients have lower mortality rates when high ratios (>1:2) of plasma or platelets to red blood cells (RBCs) are used. Blunt and penetrating trauma patients have different injury patterns and may respond differently to resuscitation. This study was performed to determine whether mortality after high product ratio massive transfusion is different in blunt and penetrating trauma patients. METHODS: Patients receiving 10 or more units of RBCs in the first 24 hours after admission to one of 23 Level I trauma centers were analyzed. Baseline physiologic and biochemical data were obtained. Univariate and logistic regression analyses were performed. Adjusted mortality in patients receiving high (≥ 1:2) and low (<1:2) ratios of plasma or platelets to RBCs was calculated for blunt and penetrating trauma patients. RESULTS: The cohort contained 703 patients. Blunt injury patients receiving a high ratio of plasma or platelets to RBCs had lower 24-hour mortality (22% vs. 31% for plasma, p = 0.007; 20% vs. 30% for platelets, p = 0.032), but there was no difference in 30-day mortality (40% vs. 44% for plasma, p = 0.085; 37% vs. 44% for platelets, p = 0.063). Patients with penetrating injuries receiving a high plasma:RBC ratio had lower 24-hour mortality (21% vs. 37%, p = 0.005) and 30-day mortality (29% vs. 45%, p = 0.005). High platelet:RBC ratios did not affect mortality in penetrating patients. CONCLUSION: Use of high plasma:RBC ratios during massive transfusion may benefit penetrating trauma patients to a greater degree than blunt trauma patients. High platelet:RBC ratios did not benefit either group.

Full Text

Duke Authors

Cited Authors

  • Rowell, SE; Barbosa, RR; Diggs, BS; Schreiber, MA; Trauma Outcomes Group, ; Holcomb, JB; Wade, CE; Brasel, KJ; Vercruysse, G; MacLeod, J; Dutton, RP; Hess, JR; Duchesne, JC; McSwain, NE; Muskat, P; Johannigamn, J; Cryer, HM; Tillou, A; Cohen, MJ; Pittet, JF; Knudson, P; De Moya, MA; Schreiber, MA; Tieu, B; Brundage, S; Napolitano, LM; Brunsvold, M; Sihler, KC; Beilman, G; Peitzman, AB; Zenait, MS; Sperry, J; Alarcon, L; Croce, MA; Minei, JP; Kozar, R; Gonzalez, EA; Stewart, RM; Cohn, SM; Mickalek, JE; Bulger, EM; Cotton, BA; Nunez, TC; Ivatury, R; Meredith, JW; Miller, P; Pomper, GJ; Marin, B

Published Date

  • August 2011

Published In

Volume / Issue

  • 71 / 2 Suppl 3

Start / End Page

  • S353 - S357

PubMed ID

  • 21814103

Pubmed Central ID

  • 21814103

Electronic International Standard Serial Number (EISSN)

  • 1529-8809

Digital Object Identifier (DOI)

  • 10.1097/TA.0b013e318227ef53

Language

  • eng

Conference Location

  • United States